Share
Market Research Report

INDIA IMMUNO-ONCOLOGY DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Segmentation
  • By Drug TypeImmune Checkpoint Inhibitors (Nivolumab, Atezolimumab, Pembrolizumab, Durvalumab) · Monoclonal Antibodies (Rituximab, Trastazumab, Bevacizumab, Nimotuzumab, Pertuzumab, Ado-Trastuzumab Emtansine) · Cancer Vaccines (Gardasil, Cervarix)
  • By Cancer TypeLung Cancer · Blood Cancer · Breast Cancer · Ovarian Cancer · Cervical Cancer · Colorectal Cancer · Stomach Cancer · Head & Neck Cancer · Others
  • By Distribution ChannelOnline Pharmacies · Retail Pharmacies · Hospital Pharmacies
  • Published In11 May 2026
  • Report CodeCMI2631
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026 - 2033

Market Segmentation

  • By Drug Type (Revenue, USD Bn, 2021-2033)

    • Immune Checkpoint Inhibitors
      • Nivolumab
      • Atezolimumab
      • Pembrolizuma
      • Durvalumab
    • Monoclonal Antibodies
      • Rituximab
      • Trastazumab
      • Bevacizumab
      • Nimotuzumab
      • Pertuzumab
      • Ado-Trastuzumab Emtansine
    • Cancer Vaccines
      • Gardasil
      • Cervarix

  • By Cancer Type (Revenue, USD Bn, 2021-2033)

    • Lung Cancer
    • Blood Cancer
    • Breast Cancer
    • Ovarian Cancer
    • Cervical Cancer
    • Colorectal Cancer
    • Stomach Cancer
    • Head & Neck Cancer
    • Others

  • By Distribution Channel (Revenue, USD Bn, 2021-2033)

    • Online Pharmacies
    • Retail Pharmacies
    • Hospital Pharmacies